Mallinckrodt to spin off generics business; BeyondSpring ready to submit approval for lead drug in China
→ Barely a month after Mallinckrodt $MNK reported a key drug failure, the company on Thursday said it was spinning off its specialty …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
